EY Is Dropping The ‘Cautious’ Optimism, Expects M&A Rebound In 2025

 
• By Joseph Haas
  
VinBrain Acuqisition
EY expects increased biopharma M&A in 2025 after a sluggish 2024 (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Strategy